JP6860652B2 - 医薬組成物 - Google Patents

医薬組成物 Download PDF

Info

Publication number
JP6860652B2
JP6860652B2 JP2019508989A JP2019508989A JP6860652B2 JP 6860652 B2 JP6860652 B2 JP 6860652B2 JP 2019508989 A JP2019508989 A JP 2019508989A JP 2019508989 A JP2019508989 A JP 2019508989A JP 6860652 B2 JP6860652 B2 JP 6860652B2
Authority
JP
Japan
Prior art keywords
administration
obinutuzumab
hour
cycle
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019508989A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528282A (ja
Inventor
マイケル ウェンガー
マイケル ウェンガー
メルダッド モバシャー
メルダッド モバシャー
チン−ウー リン
チン−ウー リン
Original Assignee
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64362606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6860652(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト filed Critical エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト
Publication of JP2019528282A publication Critical patent/JP2019528282A/ja
Priority to JP2021052571A priority Critical patent/JP7370357B2/ja
Application granted granted Critical
Publication of JP6860652B2 publication Critical patent/JP6860652B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019508989A 2017-10-19 2018-10-19 医薬組成物 Active JP6860652B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021052571A JP7370357B2 (ja) 2017-10-19 2021-03-26 医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762574297P 2017-10-19 2017-10-19
US62/574,297 2017-10-19
PCT/JP2018/038924 WO2019017499A2 (en) 2017-10-19 2018-10-19 PHARMACEUTICAL COMPOSITION

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021052571A Division JP7370357B2 (ja) 2017-10-19 2021-03-26 医薬組成物

Publications (2)

Publication Number Publication Date
JP2019528282A JP2019528282A (ja) 2019-10-10
JP6860652B2 true JP6860652B2 (ja) 2021-04-21

Family

ID=64362606

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019508989A Active JP6860652B2 (ja) 2017-10-19 2018-10-19 医薬組成物
JP2021052571A Active JP7370357B2 (ja) 2017-10-19 2021-03-26 医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021052571A Active JP7370357B2 (ja) 2017-10-19 2021-03-26 医薬組成物

Country Status (14)

Country Link
US (2) US12129304B2 (enExample)
EP (2) EP3697818B1 (enExample)
JP (2) JP6860652B2 (enExample)
KR (2) KR102766089B1 (enExample)
CN (2) CN120983618A (enExample)
AU (2) AU2018303836B2 (enExample)
BR (1) BR112020007731A2 (enExample)
CA (1) CA3079374A1 (enExample)
ES (1) ES3005784T3 (enExample)
IL (2) IL321935A (enExample)
MX (2) MX2020003418A (enExample)
PL (1) PL3697818T3 (enExample)
TW (2) TWI828593B (enExample)
WO (1) WO2019017499A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020003418A (es) * 2017-10-19 2020-07-20 Hoffmann La Roche Tratamiento de linfoma de células b positivo a cd20 con obinutuzumab.
US20240050562A1 (en) * 2019-10-04 2024-02-15 Chugai Seiyaku Kabushiki Kaisha Inhibitor of cell proliferation in obinutuzumab resistant cd20-positive cancer, and medicinal composition, medicine, production, method for inhibiting cell proliferation, therapeutic method, type ii anti-cd20 antibody, compounds, combination of same, enhancer and inducer, each relating thereto
JPWO2023042679A1 (enExample) 2021-09-17 2023-03-23

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME01775B (me) 2003-11-05 2011-02-28 Glycart Biotechnology Ag Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
NZ585516A (en) 2007-12-21 2012-07-27 Hoffmann La Roche Anti-cd20 antibody formulation
SI3179992T1 (sl) * 2014-08-11 2022-09-30 Acerta Pharma B.V. Terapevtske kombinacije zaviralca BTK, zaviralca PD-1 in/ali zaviralca PD-L1
US11149091B2 (en) * 2015-12-09 2021-10-19 Cedars-Sinai Medical Center Methods for treating nephrotic syndrome
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
JP6881583B2 (ja) 2017-07-21 2021-06-02 横浜ゴム株式会社 空気入りタイヤ
MX2020003418A (es) * 2017-10-19 2020-07-20 Hoffmann La Roche Tratamiento de linfoma de células b positivo a cd20 con obinutuzumab.

Also Published As

Publication number Publication date
IL321935A (en) 2025-09-01
US20200299398A1 (en) 2020-09-24
AU2018303836B2 (en) 2025-04-17
US12129304B2 (en) 2024-10-29
IL273909B2 (en) 2025-12-01
MX2024009217A (es) 2024-11-08
AU2018303836A1 (en) 2020-05-14
KR20240157135A (ko) 2024-10-31
BR112020007731A2 (pt) 2020-10-20
JP2019528282A (ja) 2019-10-10
PL3697818T3 (pl) 2025-03-24
EP3697818B1 (en) 2024-11-27
AU2025205481A1 (en) 2025-08-07
US20250026847A1 (en) 2025-01-23
TW202342099A (zh) 2023-11-01
TW201922284A (zh) 2019-06-16
IL273909B1 (en) 2025-08-01
WO2019017499A2 (en) 2019-01-24
EP4520347A3 (en) 2025-06-04
MX2020003418A (es) 2020-07-20
IL273909A (en) 2020-05-31
CA3079374A1 (en) 2019-01-24
JP2021152002A (ja) 2021-09-30
EP3697818A2 (en) 2020-08-26
WO2019017499A3 (en) 2019-02-21
CN120983618A (zh) 2025-11-21
TWI805630B (zh) 2023-06-21
CN111212854A (zh) 2020-05-29
KR102766089B1 (ko) 2025-02-13
ES3005784T3 (en) 2025-03-17
JP7370357B2 (ja) 2023-10-27
EP4520347A2 (en) 2025-03-12
KR20200067196A (ko) 2020-06-11
TWI828593B (zh) 2024-01-01

Similar Documents

Publication Publication Date Title
US20250026847A1 (en) Treatment of cd20-positive b-cell lymphoma with obinutuzumab
CN114641312A (zh) 抗cd19疗法与来那度胺组合用于治疗白血病或淋巴瘤
US20230014026A1 (en) Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint
JP2025522729A (ja) ガレクチン－９を阻害する抗体を用いた悪性血液疾患の処置
JP2023052642A (ja) 抗ｃｄ５２抗体を用いて多発性硬化症を処置するための経路およびスケジュール
HK40031517A (en) Treatment of cd20-positive b-cell lymphoma with obituzumab
US20220339174A1 (en) Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells
WO2025215124A2 (en) Combination treatment of glofitamab and chemotherapy
WO2025087936A1 (en) Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy in ctdna high risk patients
US20240025987A1 (en) Use of anti-il-27 antibodies
CN118871129A (zh) 抗tim-3抗体与去甲基化药物的药物组合
HK1172823A (en) Cd40 antibody formulation and methods

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200309

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200309

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20200311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200609

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210326

R150 Certificate of patent or registration of utility model

Ref document number: 6860652

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250